Enhanced CABG is in Your Hands
|
|
- Valentine Dorsey
- 5 years ago
- Views:
Transcription
1 An Intraoperative Treatment for Preserving Vascular Grafts Enhanced CABG is in Your Hands
2 Intraoperative Graft Damage is the Principal Cause of Vein Graft Failure (VGF) The durability and patency of vein grafts are significantly compromised by Vein Graft Disease (VGD): The VGD process begins with endothelial damage that occurs during the grafting surgery itself. (1) VGD encompasses the pathophysiological changes that occur in vein grafts following their use in surgical grafting. Endothelial Damage, Manifested Within Minutes as Pro-inflammatory and Pro-thrombogenic Changes Within the Graft, Leads to VGD and VGF As VGD progresses, vein grafts lose their ability to adapt to the post-grafting environment, leading to: Thrombus formation Intimal hyperplasia Atherosclerosis These may result in: Graft stenosis Occlusion Loss of graft patency Figure 1: Printed with permission from Elsevier (2) VGD that progresses to VGF may result in myocardial infarction and the need for repeat revascularization. The success rate of revascularization or re-intervention of a failed graft is very poor (3) and therefore addressing early vein graft disease in the primary graft is crucial. (1)
3 Designed for Tissue Preservation DuraGraft is an intraoperative vascular graft treatment that maintains endothelial function and structure, reducing the incidence and complications associated with graft failure thereby improving clinical outcomes. DuraGraft improves clinical outcomes by providing an environment which protects against intraoperative Ischemic Reperfusion Injury. DuraGraft is a clinically tested and approved treatment for preserving vascular grafts. ph Balanced - Heparinized saline and autologous blood are not ph balanced. Stabilized Antioxidants - Two potent antioxidants neutralize the reactive oxygen species that cause oxidative damage during ischemia (glutathione and ascorbic acid). Ionically Balanced - Critical in maintaining cell polarity, and membrane integrity. Maintains the Viability and Health of the Graft Post-Grafting - L-Arginine is included to support synthesis of nitric oxide during the ischemic period. Supports Anaerobic Metabolism - Contains components required to support anaerobic metabolism during ischemia thereby preventing the generation of metabolic stress lesions (glucose and high energy phosphates).
4 DuraGraft Clinical Study Summary DuraGraft has been proven to reduce both graft level negative remodeling and clinical complications (MI, Repeat Revascularization and MACE) associated with VGF, with statistical significance. U.S. Retrospective Study (4) 2,436 CABG Patients DuraGraft Treatment vs Standard of Care Significant reductions in long-term clinical events with DuraGraft (up to 15 years) Reduction in Myocardial Infarction Rates Unadjusted Analysis: 43% (p = <0.0001) IPW Adjusted: 45% (p = <0.0001) Reduction in Repeat Revascularization Rates Unadjusted Analysis: 31% (p = 0.002) IPW Adjusted: 35% (p = <0.037) Reduction in MACE Rates Unadjusted Analysis: 21% (p = <0.0001) IPW Adjusted: 19% (p = 0.005) Prospective, Randomized, Multi-Center Within-Patient Study (5) 5 North American and 2 European Sites Double-Blind, Comparative (Within-Person) DuraGraft Treatment vs Standard of Care mitt Population n=97 Wall thickening is an expression of intimal hyperplasia an early indicator of disease. DuraGraft treated grafts demonstrate significant reduction in wall thickening at 12 months in proportionate analyses of both whole and proximal segment of grafts. DuraGraft treated grafts also demonstrate significant reductions in both wall thickening and maximal (focal) luminal narrowing in longitudinal analyses of proximal segment of grafts from 1 to 12 months. Conclusions: Early disease is most pronounced in the proximal segment and DuraGraft mitigates early signals of graft disease.
5 The DuraGraft Difference In addition to being ph balanced and buffered, DuraGraft protects against the two main causes of Ischemic Reperfusion Injury (IRI) - Oxidative Damage and Metabolic Stress. Limitations of Saline, Blood & Buffered Solutions Saline, blood and buffered solutions are not preservation solutions and DO NOT protect against IRI. Standard of Care Property Saline Blood Buffered Solutions Approved for Indication Isotonic ph Balanced Does Not Actively Cause Harm Ionically Balanced Contains Pro-endothelial Components Prevents Ischemia Reperfusion Injury Prevents Oxidative Damage Prevents Metabolic Storage Lesions Designed to Prevent Inflammation and Pro-Coagulant Responses Preserves Vascular Endothelium Designed to Prevent Edema of Graft Tissue
6 DuraGraft is a Fully Protective Treatment Solution DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure. DuraGraft enhances CABG outcomes by reducing major cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is clinically proven to reduce complications associated with VGF post-cabg. DuraGraft is an approved treatment for preventing endothelial damage to vascular grafts. 225 Chimney Corner Lane, Suite 2001 Jupiter, FL 33458, USA DuraGraft is not available in the United States. Visit for availability. DuraGraft is a registered trademark of Somahlution All rights reserved. MKT-068 Rev Kim FY, Marhefka G, Ruggiero NJ, et al. Saphenous vein graft disease: review of pathophysiology, prevention, and treatment. Cardiol Rev 2013; 21(2): Thatte et al., Multi-photon microscopic evaluation of saphenous vein endothelium and its preservation with a new solution, GALA. Ann Thorac Surg. 2003; 75: Testa L, Bedogni F. Treatment of Saphenous Vein Graft Disease: Never Ending Story of the Eternal Return. Res Cardiovasc Med. 2014; 3(3):e Haime, M (2016) US Retrospective Study of DuraGraft vs Standard of Care presented at EACTS 2016, Barcelona, Spain; October 3, Perrault, L. (2017). A randomized multi-center trial using longitudinal MDCT angiography analysis in patients undergoing CABG; presented at TCT 2017, Denver, CO; October 30, 2017.
On-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery
On-Pump vs. Off-Pump CABG: The Controversy Continues Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery On-pump vs. Off-Pump CABG: The Controversy Continues Conflict
More informationMandatory knowledge about natural history of coronary grafts. P.Sergeant P. Maureira K.U.Leuven, Belgium
Mandatory knowledge about natural history of coronary grafts P.Sergeant P. Maureira K.U.Leuven, Belgium Types of grafts Arterial ITA/IMA (internal thoracic/mammary artery) Radial artery Gastro-epiploïc
More informationSURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS?
SURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS? Luigi Martinelli Chief, Dept. of Surgery Istituto Clinico Ligure di Alta Specialità RAPALLO During 1987 2006,
More informationCatheter Interventions for Kawasaki Disease: Current Concepts and Future Directions
REVIEW DOI 10.4070/kcj.2011.41.2.53 Print ISSN 1738-5520 / On-line ISSN 1738-5555 Copyright 2011 The Korean Society of Cardiology Open Access Catheter Interventions for Kawasaki Disease: Current Concepts
More informationPCI in Patients with Transplant Coronary Artery Disease. Michael S. Lee, MD, FACC, FSCAI Assistant Professor UCLA School of Medicine
PCI in Patients with Transplant Coronary Artery Disease Michael S. Lee, MD, FACC, FSCAI Assistant Professor UCLA School of Medicine Faculty Disclosure Honararia for Boston Scientific, BMS, Daiichi Sankyo,
More informationFFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium
FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Conflict of Interest Institutional research grants and speaker s fee from St. Jude Medical and Boston Scientic to Cardiovascular
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial
More informationPathology of Cardiovascular Interventions. Body and Disease 2011
Pathology of Cardiovascular Interventions Body and Disease 2011 Coronary Artery Atherosclerosis Intervention Goals: Acute Coronary Syndromes: Treat plaque rupture and thrombosis Significant Disease: Prevent
More informationManagement of High-Risk CAD : Surgeons Perspective
Management of High-Risk CAD : Surgeons Perspective Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Conflict : Cardiac Surgeon! High Risk CABG 77 year old with prior large anterior
More informationEAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers
EAE Teaching Course Magnetic Resonance Imaging Competitive or Complementary? Sofia, Bulgaria, 5-7 April 2012 F.E. Rademakers Complementary? Of Course N Engl J Med 2012;366:54-63 Clinical relevance Treatment
More informationDisclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb
Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes from the Project of Ex-vivo Vein Graft
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationManagement during Reoperation of Aortocoronary Saphenous Vein Grafts with Minimal Atherosclerosis by Angiography
Management during Reoperation of ortocoronary Saphenous Vein Grafts with therosclerosis by ngiography William G. Marshall, Jr., M.D., Jeffrey Saffitz, M.D., and Nicholas T. Kouchoukos, M.D. STRCT The proper
More informationFinal Kissing Ballooning Returns? The analysis of COBIS II registry
Final Kissing Ballooning Returns? The analysis of COBIS II registry Hyeon- Cheol Gwon Heart Vascular & Stroke Ins?tute, Samsung Medical Center Sungkyunkwan University School of Medicine Final Kissing Ballooning
More informationDiabetes and Occult Coronary Artery Disease
Diabetes and Occult Coronary Artery Disease Mun K. Hong, MD, FACC, FSCAI Director, Cardiac Catheterization Laboratory & Interventional Cardiology St. Luke s-roosevelt Hospital Center New York, New York
More informationStable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology
Stable Ischemic Heart Disease Ivan Anderson, MD RIHVH Cardiology Outline Review of the vascular biology of atherosclerosis Why not just cath everyone with angina? Medical management of ischemic cardiomyopathy
More informationOPCAB IS NOT BETTER THAN CONVENTIONAL CABG
OPCAB IS NOT BETTER THAN CONVENTIONAL CABG Harold L. Lazar, M.D. Harold L. Lazar, M.D. Professor of Cardiothoracic Surgery Boston Medical Center and the Boston University School of Medicine Boston, MA
More informationIschemic heart disease
Ischemic heart disease Introduction In > 90% of cases: the cause is: reduced coronary blood flow secondary to: obstructive atherosclerotic vascular disease so most of the time it is called: coronary artery
More informationDeclaration of conflict of interest NONE
Declaration of conflict of interest NONE Claudio Muneretto MD, PhD Director of Division of Cardiac Surgery University of Brescia Medical School Italy Hybrid Chymera Different features and potential advantages
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationSung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center
CMR Perfusion and Viability A STICH Out of Time? Sung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center Can Imaging Improve
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationPERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW
PERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW Bruce Biccard Perioperative Research Group, Department of Anaesthetics 18 June 2015 Disclosure Research funding received Medical Research
More informationPathophysiology of Coronary Microvascular Dysfunction
Pathophysiology of Coronary Microvascular Dysfunction Cheol Woong Yu, MD, PhD Cardiology Department Division of Internal Medicine Korea University Anam Hospital. Etiologies of Chest Pain without obstructive
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationSirolimus-Eluting Stents for Treatment of In-Stent Restenosis
Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique
More informationApproach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
More informationMyocardial viability testing. What we knew and what is new
Myocardial viability testing. What we knew and what is new Dr B K S Sastry, MD, DM. CARE Hospitals, Hyderabad What is Viability Viability Dysfunctional myocardium subtended by diseased coronary arteries
More informationMR Assessment of Myocardial Viability
MR Assessment of Myocardial Viability Definition of Viability Clinical Metabolism: Presence of glucose uptake Perfusion / Perfusion reserve Morphology: Wall thickness, wall thickening Contractility: Recovery
More informationIschemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Phy
Ischemic Postconditioning During Primary Percutaneous Coronary Intervention Mechanisms and Clinical Application Jian Liu, MD FACC FESC FSCAI Chief Physician, Professor of Medicine Department of Cardiology,
More informationManagement of Cardiogenic shock. Prof. Christian JM Vrints
Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationAccepted Manuscript. Cesario F. Bianchi, MD, PhD, FAHA, Orlando Petrucci, MD, PhD
Accepted Manuscript A better treatment for Safenous Vein Graft Disease after Coronary Artery Bypass Surgery: May statins be the answer at the Right Dose to the Right Patient at the Right Time? Cesario
More informationCLINICAL CONSEQUENCES OF THE
CLINICAL CONSEQUENCES OF THE FAME STUDY TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands GUIDELINES ESC SEPTEMBER 2010 FFR UPGRADED TO LEVEL
More informationWhy I try to avoid side branch dilatation
Why I try to avoid side branch dilatation Hyeon-Cheol Gwon Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Why I don t kiss? I kiss! I prefer to discuss SB ballooning rather
More informationOff Pump CABG is Dead. Hopeman Lecture Debate T. Brett Reece, MD September 10, 2007
Off Pump CABG is Dead Hopeman Lecture Debate T. Brett Reece, MD September 10, 2007 OPCAB Potential Pitfalls Technically Demanding Steep learning curve Incomplete revascularization Intraoperative ischemia
More informationIntended Learning Outcomes
2011 Acute Limb Ischemia Definition, Etiology & Pathophysiology Clinical Evaluation Management Ali SABBOUR Prof. of Vascular Surgery, Ain Shams University Acute Limb Ischemia Intended Learning Outcomes
More informationPercutanous revascularization of chronic total occlusion of diabetic patients at Iraqi center for heart diseases, a single center experience 2012
www.muthjm.com Muthanna Medical Journal 2015; 2(2):76-82 Percutanous revascularization of chronic total occlusion of diabetic patients at Iraqi center for heart diseases, a single center experience 2012
More informationPathology of Coronary Artery Disease
Pathology of Coronary Artery Disease Seth J. Kligerman, MD Pathology of Coronary Artery Disease Seth Kligerman, MD Assistant Professor Medical Director of MRI University of Maryland Department of Radiology
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationChest pain affects 20% to 40% of the general population during their lifetime.
Chest pain affects 20% to 40% of the general population during their lifetime. More than 5% of visits in the emergency department, and up to 40% of admissions are because of chest pain. Chest pain is a
More informationVentricular Function and the Native Coronary Circulation Five Years after Myocardial Revascularhation
Ventricular Function and the Native Coronary Circulation Five Years after Myocardial Revascularhation Denis H. Tyras, M.D., Naseer Ahmad, M.D., George C. Kaiser, M.D., Hendrick B. Barner, M.D., John E.
More informationTYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016
TYPE II MI KC ACDIS LOCAL CHAPTER March 8, 2016 TYPE 2 MI DEFINITION: Acute coronary syndrome (ACS) encompasses a continuum of myocardial ischemia and infarction, which can make the diagnostic and coding
More informationMaster Eudipharm 2012 Introductory Module, Principles of Discovery of Medicine and Development Planning. Nathan Mewton, MD, PhD. September 26 th 2012
Master Eudipharm 2012 Introductory Module, Principles of Discovery of Medicine and Development Planning * Nathan Mewton, MD, PhD. September 26 th 2012 *A little bit of History *Rabies a viral disease that
More informationCAROTID ARTERY ANGIOPLASTY
CAROTID ARTERY ANGIOPLASTY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationTCT mdbuyline.com Clinical Trial Results Summary
TCT 2012 Clinical Trial Results Summary FAME2 Trial: FFR (fractional flow reserve) guided PCI in all target lesions Patients with significant ischemia, randomized 1:1 Control arm: not hemodynamically significant
More informationTHROMBOSIS. Dr. Nisreen Abu Shahin Assistant Professor of Pathology Pathology Department University of Jordan
THROMBOSIS Dr. Nisreen Abu Shahin Assistant Professor of Pathology Pathology Department University of Jordan NORMAL BLOOD VESSEL HISTOLOGY THROMBOSIS Pathogenesis (called Virchow's triad): 1. Endothelial*
More informationFFR Incorporating & Expanding it s use in Clinical Practice
FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel
More informationChronic Total Occlusions. Stephen Cook, MD Medical Director, Cardiac Catheterization Laboratory Oregon Heart & Vascular Institute
Chronic Total Occlusions Stephen Cook, MD Medical Director, Cardiac Catheterization Laboratory Oregon Heart & Vascular Institute Financial Disclosures /see -tee-oh / abbr. Med. Chronic Total Occlusion,
More informationEndovascular Should Be Considered First Line Therapy
Revascularization of Patients with Critical Limb Ischemia Endovascular Should Be Considered First Line Therapy Michael Conte David Dawson David L. Dawson, MD Revised Presentation Title A Selective Approach
More informationPathophysiology and treatment of focal cerebral ischemia
J Neurosurg 77: 169-184, 1992 Review Article Pathophysiology and treatment of focal cerebral ischemia Part I: Pathophysiology Bo K. SIESJO, M.D. Laborutory for Experimental Bruin Reseurch, Experrmc~ntul
More informationAcute coronary syndrome. Dr LM Murray Chemical Pathology Block SA
Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,
More informationMyocardial Infarction
Myocardial Infarction MI = heart attack Defined as necrosis of heart muscle resulting from ischemia. A very significant cause of death worldwide. of these deaths, 33% -50% die before they can reach the
More informationCoronary atherosclerotic heart disease remains the number
Twenty-Year Survival After Coronary Artery Surgery An Institutional Perspective From Emory University William S. Weintraub, MD; Stephen D. Clements, Jr, MD; L. Van-Thomas Crisco, MD; Robert A. Guyton,
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationQuality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationImportance of the third arterial graft in multiple arterial grafting strategies
Research Highlight Importance of the third arterial graft in multiple arterial grafting strategies David Glineur Department of Cardiovascular Surgery, Cliniques St Luc, Bouge and the Department of Cardiovascular
More informationManagement of Multivessel CAD: Stenting or CABG?
Management of Multivessel CAD: Stenting or CABG? Filippos Triposkiadis, MD, FESC, FACC Department of Cardiology, University of Thessaly Long-term Outcome of Patients With 3VD Undergoing CABG A Report from
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationTHE COMPLEX RELATION BETWEEN VULNERABILITY AND ISCHEMIA a paradigm shift
THE COMPLEX RELATION BETWEEN VULNERABILITY AND ISCHEMIA a paradigm shift Angioplasty Summit TCT ASIA Seoul, Korea, april 23rd, 2008 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands
More informationFractional Flow Reserve: Review of the latest data
Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most
More informationThe Value of Stress MRI in Evaluation of Myocardial Ischemia
The Value of Stress MRI in Evaluation of Myocardial Ischemia Dr. Saeed Al Sayari, MBBS, EBCR, MBA Department of Radiology and Nuclear Medicine Mafraq Hospital, Abu Dhabi United Arab Emirates Introduction
More informationCardiac, Vascular and Transplant Surgery Quality Assessment. Intraoperative Ultrasound Imaging and TTFM
Cardiac, Vascular and Transplant Surgery Quality Assessment Intraoperative Ultrasound Imaging and TTFM Reduce risk of early graft failure, stroke, myocardial infarction or recurrent angina and provide
More informationATHEROSCLEROSIS. Secondary changes are found in other coats of the vessel wall.
ATHEROSCLEROSIS Atherosclerosis Atherosclerosis is a disease process affecting the intima of the aorta and large and medium arteries, taking the form of focal thickening or plaques of fibrous tissue and
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More informationRecommendations for Follow-up After Vascular Surgery Arterial Procedures SVS Practice Guidelines
Recommendations for Follow-up After Vascular Surgery Arterial Procedures 2018 SVS Practice Guidelines vsweb.org/svsguidelines About the guidelines Published in the July 2018 issue of Journal of Vascular
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationINNOVATION THAT REALLY MATTERS. Prof. Lina Badimon. Institut Català de Ciències Cardiovasculars (ICCC), Barcelona
INNOVATION THAT REALLY MATTERS Prof. Lina Badimon, Barcelona THE INSTITUTION THE INSTITUTION THE ICCC CATALAN INSTITUTE FOR CARDIOVASCULAR SCIENCE (ICCC) Objectives LEADING AN STRATEGIC PLANNING IN CVR
More informationDistal Coronary Artery Dissection Following Percutaneous Transluminal Coronary Angioplasty
Distal Coronary rtery Dissection Following Percutaneous Transluminal Coronary ngioplasty Douglas. Murphy, M.D., Joseph M. Craver, M.D., and Spencer. King 111, M.D. STRCT The most common cause of acute
More information2010 ACLS Guidelines. Primary goals of therapy for patients
2010 ACLS Guidelines Part 10: Acute Coronary Syndrome Present : 內科 R1 鍾伯欣 Supervisor: F1 吳亮廷 991110 Primary goals of therapy for patients of ACS Reduce the amount of myocardial necrosis that occurs in
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationPedal Bypass With Deep Venous Arterialization:
Pedal Bypass With Deep Venous Arterialization: Long Term Result For Critical Limb Ischemia With Unreconstructable Distal Arteries Pramook Mutirangura Professor of Vascular Surgery Faculty of Medicine Siriraj
More informationCoronary Artery Disease in the 21 st Century: An Integrated Approach Based on Science and Art
Coronary Artery Disease in the 21 st Century: An Integrated Approach Based on Science and Art Harisios Boudoulas, MD, Dr, Dr. Hon. Professor, Honorary Professor, Academician Development of Coronary Artery
More informationWhich Cyanotic Patient Needs Anticoagulation?
Which Cyanotic Patient Needs Anticoagulation? Erwin Oechslin, MD, FRCPC, FESC Director, Adult Congenital Heart Disease Program The Bitove Family Professor of ACHD Professor of Medicine, U of T Peter Munk
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationReperfusion Injury: How Can We Reduce It?
MI/CAD: Practical Question in Management of AMI Patients Reperfusion Injury: How Can We Reduce It? Hyun-Jai Cho, M.D., Ph.D Cardiovascular Center & Department of Internal Medicine Seoul National University
More informationIschemic Mitral Valve Disease: Repair, Replace or Ignore?
Ischemic Mitral Valve Disease: Repair, Replace or Ignore? Fabio B. Jatene Full Professor of Cardiovascular Surgery, Medical School, University of São Paulo, Brazil DISCLOSURE I have no financial relationship
More informationNovel Concept Regenerative, Immune-Privileged, Bio-Stentgraft
Novel Concept Regenerative, Immune-Privileged, Bio-Stentgraft Bruce M. Gordon, DO, FACC Advanced Heart Care, PA The Heart Hospital Baylor Plano, Texas Director, Cardiac Catheterization Lab, Denton, TX
More informationIntervention: How and to which extent is technology helping us?
Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction
More informationUPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18
UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment
More informationWatermark. Interaction between Neuropathy and PAD
Interaction between Neuropathy and PAD Javier La Fontaine, DPM, MS Associate Professor Department of Plastic Surgery UT Southwestern Medical Center Dallas, Texas Objectives Understand vascular disease
More informationA CRITICAL ANALYSIS OF ORGAN PERFUSION SOLUTIONS IN LIVER TRANSPLANTATION
A CRITICAL ANALYSIS OF ORGAN PERFUSION SOLUTIONS IN LIVER TRANSPLANTATION John J. Fung, MD Director, Cleveland Clinic Health System Center for Transplantation Disclosure: I have been a consultant for Dupont,
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationMultimodality Imaging in Spontaneous Coronary Artery Dissection in the Peripartum Period
Multimodality Imaging in Spontaneous Coronary Artery Dissection in the Peripartum Period Marysia Tweet, MD NASCI Annual Meeting October 18 th, 2016 2016 MFMER slide-1 DISCLOSURE No relevant financial relationship(s)
More informationCASE REPORT AIR VENT OF VEIN GRAFT IN EXTRACRANIAL-INTRACRANIAL BYPASS SURGERY
Nagoya J. Med. Sci. 74. 339 ~ 345, 2012 CASE REPORT AIR VENT OF VEIN GRAFT IN EXTRACRANIAL-INTRACRANIAL BYPASS SURGERY HIROFUMI OYAMA, AKIRA KITO, HIDEKI MAKI, KENICHI HATTORI, TOMOYUKI NODA and KENTARO
More information가천의대길병원소아심장과최덕영 PA C IVS THE EVALUATION AND PRINCIPLES OF TREATMENT STRATEGY
가천의대길병원소아심장과최덕영 PA C IVS THE EVALUATION AND PRINCIPLES OF TREATMENT STRATEGY PA c IVS (not only pulmonary valve disease) Edwards JE. Pathologic Alteration of the right heart. In: Konstam MA, Isner M, eds.
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationAccepted Manuscript. Late venous graft failure: mystery solved? Siamak Mohammadi, MD, FRCSC, Dimitri Kalavrouziotis, MD, FRCSC
Accepted Manuscript Late venous graft failure: mystery solved? Siamak Mohammadi, MD, FRCSC, Dimitri Kalavrouziotis, MD, FRCSC PII: S0022-5223(18)32542-X DOI: 10.1016/j.jtcvs.2018.09.038 Reference: YMTC
More informationMultivessel Coronary Artery Disease : CABG. Zürich, F. Siclari MD
Multivessel Coronary Artery Disease : CABG Zürich, 10.06.2015 F. Siclari MD Coronary Artery Ruptured Plaque Pathological process with definite subsequent vascular changes most of them irreversible CABG
More informationRationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
More informationPlaque Shift vs. Carina Shift Prevalence and Implication
TCTAP 2013 Fellowship Course Left Main and Bifurcation PCI: Bifurcation PCI Plaque Shift vs. Carina Shift Prevalence and Implication Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan
More information